News

USA: Low-Risk Novel Products Can Avoid Automatic Class III Designation from US FDA – March, 2022

USA: Low-Risk Novel Products Can Avoid Automatic Class III Designation from US FDA – March, 2022

  • 2022-03-25 11:58:47

The US Food and Drug Administration (FDA) has updated several regulations affecting De Novo classification of novel medical devices. The main purpose is to present an objective and balance for the scientific evidence to be the foundation to grant a De Novo request. Also, the De Novo products will serve as future predicate devices for prospective 510(k) registration applications to improve and extend the existing 510(k) database.

More
USA: New Exemption List for Class II Products – September, 2020

USA: New Exemption List for Class II Products – September, 2020

  • 2020-09-15 09:09:58

After a lengthy discussion, the U.S. Food and Drug Administration (FDA) released the final determination of the exempt list for the premarket notification (510 k). The exemption list is immediately in effect after July 22nd, 2020. We summarize the Agency's final determination information from the FDA for you.

More